Abstract
In Part 1 of the phase 3 CASSIOPEIA trial, patients (pts) received four 28-day pre-autologous stem cell transplant (ASCT) induction and two 28-day post-ASCT consolidation cycles of D-VTd or VTd. D-VTd improved progression-free survival (PFS) and rates of stringent complete response (sCR) and minimal residual disease (MRD) vs VTd alone. Overall survival (OS) remains immature. In Part 2 (ongoing), pts were re-randomized to daratumumab maintenance or observation for 2 yrs. In the phase 3 IFM2009 trial, all pts received three 21-day cycles VRd induction followed by either an additional 5 cycles of VRd or ASCT followed by 2 post-ASCT consolidation cycles of VRd (all pts then received 1 yr lenalidomide maintenance).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
